Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Comparison of CMF Versus Sequential Epirubicin Followed by SMF as Adjuvant Chemotherapy for Women With Early Breast Cancer

NCT00003012 is registered in ClinicalTrials.gov with Scottish Cancer Therapy Network as lead sponsor.

NCT NCT00003012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Comparison of CMF Versus Sequential Epirubicin Followed by SMF as Adjuvant Chemotherapy for Women With Early Breast Cancer
Lead sponsor
Scottish Cancer Therapy Network
Phase
Phase 3
Overall status
Completed
Start date
October 31, 1996
Completion date
Not reported
Enrollment
1,000 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer